Study title: An open, controlled, randomized and single-centre study to evaluate the effectiveness of a new economical schedule of rabies postexposure prophylaxis using purified chick embryo cell tissue culture (PCEC) rabies vaccine (RabipurĀ®, Behring Vaccines; now Novartis Vaccines) in the patients of 1 to 61 years of age.
Type of medicine: Non-centrally authorised vaccines | |||||
Therapeutic area: Virus Diseases | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: RABIES VACCINE FOR HUMAN USE PREPARED FROM CELL CULTURE (DIPLOID CELLS) | |||||
ATC code: J07BG01 | |||||
Document link: | |||||
Document date: 2014-10-07 | |||||
Study number: 7T-301IP-A | |||||
EudraCT number: | |||||
Scope of study: Observational study | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |